HCC Clinical Trial - Pembrolizumab in Hepatocellular Carcinoma

Status Active, not recruiting

Clinical Trial Summary

This is a single-arm Phase II trial of pembrolizumab in patients with hepatitis B virus-related hepatocellular carcinoma with parallel study on baseline and serial change in the immune environment. Subjects should have a confirmed diagnosis of HCC (in accordance with the AASLD guideline) and confirmed chronic infection with hepatitis B virus as defined by positivity for HBsAg. Antiviral therapy for HBV must be given for at least 12 weeks and HBV viral load must be less than 100 IU/mL prior to first dose of study drug. They must have disease not amenable to a curative treatment approach or loco-ablation. Subject must be fit and agreeable with baseline and post-treatment biopsy of tumor. Subjects must have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 and adequate organ functions. 30 subjects will be enrolled to receive pembrolizumab 200 mg IV every 3 weeks(Q3W). Pre-treatment and on-treatment biopsy after 2 cycles of Pembrolizumab will be preformed. Treatment will be stopped when progression of disease or intolerable toxicity occurs. The primary objectives of this trial are to study the efficacy and safety of pembrolizumab in patients with HBV-related HCC and to study the serial change in RNA expression of immune-related gene panel in post-treatment biopsy tissue. The secondary objectives of this trial are to study the serial change in cytokine profile between pre-treatment and post-treatment samples, to study the PD-L1 immunohistochemical (IHC) expression in tumor sample at baseline and post-treatment tissue samples and to study the presence of tumor infiltrating lymphocytes in the baseline and post-treatment tumor samples. The exploratory objective of this trial is to evaluate the possibility of using baseline and the serial change in RNA expression of immune-related gene panel or PD-L1/2 IHC to predict treatment response.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03419481
Study type	Interventional
Source	Chinese University of Hong Kong
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	April 30, 2018
Completion date	December 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05458115` - Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
Not yet recruiting	`NCT05022628` - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis	Phase 4
Enrolling by invitation	`NCT02256514` - Open Label Trial of Immunotherapy for Advanced Liver Cancer	Phase 2
Not yet recruiting	`NCT06434480` - SBRT in HCC With Oligoprogression on Atezo-Bev	N/A
Completed	`NCT04542837` - The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma	Phase 2
Not yet recruiting	`NCT05025592` - cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
Completed	`NCT04172506` - A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT06024252` - Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Not yet recruiting	`NCT05840133` - Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
Terminated	`NCT02785874` - Statin With Palliative Therapy for HCC	N/A
Not yet recruiting	`NCT02715492` - Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.	Phase 3
Completed	`NCT02985034` - Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT	N/A
Not yet recruiting	`NCT06069947` - SALT for Liver Cirrhosis With HCC	N/A
Recruiting	`NCT05581004` - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Phase 1
Suspended	`NCT02935478` - Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation	N/A
Recruiting	`NCT05592171` - Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC	N/A
Completed	`NCT03176485` - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors	N/A
Recruiting	`NCT05544253` - Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC	Phase 2/Phase 3
Recruiting	`NCT06184152` - CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Completed	`NCT02675920` - A Study of HCC High Risk Group Using Two Surveillance Tools